for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

DelMar Pharmaceuticals Inc

DMPI.OQ

Latest Trade

0.49USD

Change

-0.03(-6.46%)

Volume

44,080

Today's Range

0.48

 - 

0.53

52 Week Range

0.40

 - 

6.95

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.52
Open
0.52
Volume
44,080
3M AVG Volume
17.60
Today's High
0.53
Today's Low
0.48
52 Week High
6.95
52 Week Low
0.40
Shares Out (MIL)
11.39
Market Cap (MIL)
5.53
Forward P/E
-0.77
Dividend (Yield %)
--

Next Event

Q1 2020 DelMar Pharmaceuticals Inc Earnings Release

Latest Developments

More

DelMar Says During Audit For Year-Ended June 30, 2019, Material Weakness In Operating Effectiveness Of Internal Controls Over Financial Reporting Was Identified

DelMar Pharmaceuticals Files For Offering 6 Mln Shares Of Common Stock

DelMar Pharmaceuticals Enrolls First Patient In The Recently-Approved Adjuvant Setting Arm Of Phase 2 Study Of VAL-083

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About DelMar Pharmaceuticals Inc

DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications. VAL-083 is an alkylating agent, which crosses the blood-brain-barrier (BBB).

Industry

Biotechnology & Drugs

Contact Info

999 Broadway W Suite 720

+1.604.2021384

http://www.delmarpharma.com/

Executive Leadership

Robert E. Hoffman

Chairman of the Board

Saiid Zarrabian

President, Chief Executive Officer, Director

Scott Praill

Chief Financial Officer

Dennis M. Brown

Chief Scientific Officer, Director

John K. Bell

Lead Independent Director

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-7.400

2018

-5.400

2019

-3.160

2020(E)

-0.630
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-217.41
Return on Equity (TTM)
-144.86

Latest News

Latest News

BRIEF-DelMar Pharmaceuticals Presents Positive Updates on 2 Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM

* DELMAR PHARMACEUTICALS PRESENTS POSITIVE UPDATES ON TWO ONGOING CLINICAL TRIALS WITH VAL-083 FOR TREATMENT OF MGMT-UNMETHYLATED GBM

BRIEF-Delmar Pharmaceuticals To Increase Number Of Authorized Shares Of Stock, Par Value Of $0.001, Per Share From 50 Mln Shares To 70 Mln Shares

* TO INCREASE NUMBER OF AUTHORIZED SHARES OF STOCK, PAR VALUE OF $0.001, PER SHARE FROM 50 MILLION SHARES TO 70 MILLION SHARES Source text: (https://bit.ly/2GWHkzx) Further company coverage:

BRIEF-Delmar Pharmaceuticals Q2 Loss Per Share $0.14

* DELMAR PHARMACEUTICALS ANNOUNCES SECOND QUARTER FISCAL YEAR 2018 FINANCIAL RESULTS

BRIEF-DelMar Pharmaceuticals Announces Fast Track Designation For VAL-083 In Recurrent Glioblastoma

* DELMAR PHARMACEUTICALS ANNOUNCES FAST TRACK DESIGNATION FOR VAL-083 IN RECURRENT GLIOBLASTOMA

BRIEF-Delmar Pharmaceuticals' interim CEO Saiid​ ‍Zarrabian reports purchase of 60,900 shares of co's common stock on Nov 14

* Delmar Pharmaceuticals Inc interim CEO Saiid Zarrabian reports purchase of 60,900 shares of co's common stock on nov 14 - SEC Filing Source text: (http://bit.ly/2hydYIN) Further company coverage:

BRIEF-Delmar Pharmaceuticals names Saiid Zarrabian interim CEO

* Delmar Pharmaceuticals appoints Saiid Zarrabian as interim chief executive officer

BRIEF-DelMar Pharmaceuticals CEO Jeffrey​ Bacha buys 10,000 shares of co's common stock on Oct 6

* DelMar Pharmaceuticals Inc CEO Jeffrey Bacha reports open market puchase of 10,000 shares of co's common stock on Oct 6 - SEC filing Source text: (http://bit.ly/2kDnPBr) Further company coverage:

BRIEF-DelMar Pharmaceuticals announces $10 million registered direct offering

* Announces $10 million registered direct offering priced at-the-market

BRIEF-Delmar Pharmaceuticals receives IND allowance from FDA

* Delmar Pharmaceuticals receives IND allowance from FDA to initiate clinical trials of VAL-083 for the treatment of ovarian cancer Source text for Eikon: Further company coverage:

BRIEF-Delmar Pharmaceuticals initiates phase 2 clinical trial

* Delmar Pharmaceuticals initiates phase 2 clinical trial in newly diagnosed MGMT-unmethylated glioblastoma multiforme

BRIEF-Delmar Pharmaceuticals HGRAC approves application to initiate phase 2 of VAL-083

* Delmar Pharmaceuticals receives approval from China's Human Genetic Resources Administration to initiate phase 2 clinical trial in newly diagnosed GBM

BRIEF-Delmar Pharmaceuticals reports completion of first site initiation visit for star-3 pivotal phase 3 clinical trial of val-083 in refractory GBM

* Delmar Pharmaceuticals announces completion of first site initiation visit for star-3 pivotal phase 3 clinical trial of val-083 in refractory gbm

BRIEF-Delmar Pharmaceuticals appoints Saiid Zarrabian to board

* Delmar Pharmaceuticals appoints Saiid Zarrabian to the board of directors and names Erich Mohr as chairman

BRIEF-DelMar Pharmaceuticals receives institutional review board approval for pivotal phase 3 clinical trial of VAL-083 in refractory GBM

* DelMar Pharmaceuticals receives institutional review board approval for pivotal phase 3 clinical trial of VAL-083 in refractory GBM

BRIEF-Delmar Pharmaceuticals announces Q3 loss per share $0.18

* Delmar Pharmaceuticals announces third quarter fiscal year 2017 financial results

BRIEF-Delmar formalizes collaboration with PRA Health Sciences for phase 3 trial of val-083

* Delmar formalizes collaboration with PRA Health Sciences for phase 3 trial of val-083 in recurrent glioblastoma multiforme (gbm)

BRIEF-Franklin Resources reports 13.2 pct passive stake in Delmar Pharmaceuticals

* Franklin Resources Inc reports 13.2 percent passive stake in Delmar Pharmaceuticals Inc as of April 30 - sec filing Source text : http://bit.ly/2pA7TOh Further company coverage:

BRIEF-Delmar Pharmaceuticals collaborates with Duke University to explore VAL-083

* Delmar Pharmaceuticals collaborates with Duke University to explore VAL-083 as a front-line treatment for glioblastoma multiforme

BRIEF-DelMar Pharma priced offering of 2.8 mln shares,warrants to purchase an aggregate of 2.1 mln shares

* DelMar Pharmaceuticals announces pricing of $9,000,000 public offering of common stock and warrants

BRIEF-Delmar Pharmaceuticals provides VAL-083 updates from ongoing American Association For Cancer Research annual meeting

* Delmar pharmaceuticals provides val-083 updates from the ongoing American Association For Cancer Research (AACR) annual meeting

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up